© 2003 by Oxford University Press
Journal of the National Cancer Institute, Vol. 95, No. 5, 348-349,
March 5, 2003
© 2003 Oxford University Press
NEWS |
Biotech Industry Tries to Recover from 2-Year Lull
| The first 10% of the full text of this article appears below. |
The biotechnology industry has not fared well in the last 2 years. Company valuations and stock prices plummeted, clinical trial results disappointed, and financings became rare. Last July, both the American Stock Exchange and the NASDAQ Biotech Indexes sank to their lowest since late 1998. The American Stock Exchange Biotech Index fell 42% last year after rising 62% in 2000 and dropping 8.5% in 2001.
Although more than 370 biotechnology drugs are in the clinic or awaiting approval—the most ever, with more than half of them cancer drugs—fewer drugs were approved in the past 2 years than in the years before them, said Steven Burrill, head of Burrill & Co., a San Francisco-based life sciences merchant bank. Ninety percent of companies’ stock prices were down last year, with
The Decline
Long-Term Investment
Cancer Drug Approval
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Y. Rhee Carpe Diem. Retooling the "Publish or Perish" Model into the "Share and Survive" Model Plant Physiology, February 1, 2004; 134(2): 543 - 547. [Full Text] [PDF]
|
|